Rapamycin, a well-established selective mTOR inhibitor, reactivates AKT via mammalian target of rapamycin complex 2 (mTORC2) signaling in several lung cancer cell lines, including A549, H358, and H460 but not HL-60 leukemia cells [26,27,28]. Here, MTOR is linked to leukemia.